(d) On August 12, 2009, the Board of Directors (the "Board") of Antares Pharma, Inc. (the "Company") increased the size of the Board to seven members and, upon the recommendation of the Governance and Nominating Committee of the Board, appointed Eamonn P. Hobbs to the Board as a Class II Director and as a member of the Audit Committee of the Board. Mr. Hobbs' term will expire at the Company's 2012 Annual Meeting of Stockholders.

Following his appointment, and consistent with the Company's independent director compensation plan (the "Plan"), the Company granted Mr. Hobbs an option to purchase 20,000 shares of the Company's common stock at an exercise price per share of $0.95, the closing price per share of the Company's common stock on the date of the grant. Under the terms of the Plan, Mr. Hobbs will also receive an option to purchase 30,000 shares of the Company's common stock, at an exercise price of the closing price per share of the Company's common stock on the date of the grant, at the time of the Company's Annual Meeting of Stockholders and an annual retainer of $25,000. In addition, Mr. Hobbs will receive an annual retainer of $5,000 for his service as a member of the Audit Committee of the Board.

A copy of the Company's press release announcing the appointment of Mr. Hobbs to the Board is attached hereto as Exhibit 99.1.

(d) Exhibits.

Exhibit Description
99.1    Press Release by Antares Pharma, Inc., dated August 12, 2009,
        announcing the appointment of Eamonn P. Hobbs to the Board of
        Directors.